Choreo LLC Purchases New Position in Catalyst Pharmaceuticals, Inc. $CPRX

Choreo LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 3rd quarter, HoldingsChannel reports. The firm acquired 20,895 shares of the biopharmaceutical company’s stock, valued at approximately $412,000.

A number of other institutional investors also recently modified their holdings of CPRX. Goldman Sachs Group Inc. increased its holdings in Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after purchasing an additional 333,100 shares in the last quarter. Geode Capital Management LLC boosted its stake in Catalyst Pharmaceuticals by 3.7% in the second quarter. Geode Capital Management LLC now owns 2,866,683 shares of the biopharmaceutical company’s stock worth $62,214,000 after purchasing an additional 101,127 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Catalyst Pharmaceuticals by 30.6% during the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after purchasing an additional 554,200 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 233.9% during the second quarter. American Century Companies Inc. now owns 1,757,988 shares of the biopharmaceutical company’s stock worth $38,148,000 after purchasing an additional 1,231,419 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Catalyst Pharmaceuticals by 0.6% in the second quarter. Boston Partners now owns 1,282,722 shares of the biopharmaceutical company’s stock valued at $27,928,000 after buying an additional 7,397 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on CPRX shares. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Oppenheimer reiterated an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $34.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $24.24 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $26.58. The company’s 50 day moving average price is $23.85 and its two-hundred day moving average price is $22.34. The company has a market capitalization of $2.96 billion, a P/E ratio of 14.34, a price-to-earnings-growth ratio of 0.72 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).